« Arbios Granted FDA Allowance To Expand SEPET(TM) Clinical Trial Eligibility | Main | Nasutra, LLC Issues a Voluntary Nationwide Recall, a Product Marketed »

FDA Statement Regarding New Trasylol Data The U.S. Food and


FDA Statement Regarding New Trasylol Data
The U.S. Food and Drug Administration (FDA) is evaluating new data provided to the Agency this week regarding the risk-benefit profile of Trasylol (aprotinin injection), a drug used to prevent blood loss during surgery.
 

©2006 FDA-News.com. All rights reserved.